Endpoints News – The biopharma world is here

SUBSCRIBE

top stories

Tesla chief Elon Musk teams up with Covid-19 player CureVac to build 'RNA microfactories'

1 hour ago

IPO bound? A Bay Area biotech grabs a mega-round on the road to a pivotal neurodegeneration program

37 minutes ago

Regeneron co-founder George Yancopoulos offers a combative defense of the police at a high school commencement. It ...

23 hours ago

Latest

Novartis loses biosimilar appeal as court upholds a 31-year monopoly by Amgen's Enbrel

27 minutes ago

FDA approvals roundup: Zogenix's Fintepla, Ultragenyx's Dojolvi, and Genentech's Phesgo

50 minutes ago

Ionis, leading MS researcher throw antisense at a new type of neuron

21 hours ago

Pfizer shares surge on positive impact of their mRNA Covid-19 vaccine — partnered with BioNTech — in an ...

21 hours ago

see latest stream

People

Elias Zerhouni discusses ‘amateur hour’ in DC, the destruction of infectious disease R&D and how we need to prep ...

Yesterday

EMA nominates Emer Cooke as executive director to replace Guido Rasi

6 days ago

Sangamo splits the R from the D in a reorganization — and bids chief farewell

Last week

Startups

Out of jobs, a pair of early cell therapy executives went to Seoul, came back with a new company, $70M and a plan to ...

6 days ago

Yale spinout re-engineers an immunotherapy GSK, others once abandoned

Last week

A virtual biotech incubator is launching with the help of Evotec and Samsara, looking for a few good scientists in ...

Last week

Deals

An experienced biotech is stitched together from transpacific parts, with 265 staffers and a focus on ‘new ...

Yesterday

Back to the immunology drawing board, AbbVie inks discovery deal with old Allergan partner

Last week

In an unexpected twist, CSL buys worldwide rights to uniQure's PhIII hemophilia B gene therapy in $2B-plus deal

Last week

IPOs

Freeline nabs $120M, eyes IPO as its gene therapy comes into focus

2 days ago

The biotech IPO boom is becoming ‘historic’ as four more throw their hats in

3 days ago

Novartis-backed Poseida is packing in the cash for its next-gen CAR-T work, adding a $110M venture raise on top of ...

6 days ago

All of the news, delivered with full-text to your inbox. For professionals discovering, developing, and marketing biopharmaceutical drugs.

SUBSCRIBE NOW

Subscribe to Endpoints News

Premium storiesSee all

Day one: The disruptor-in-chief at BridgeBio invites Brent Saunders onto the board

Last week

What’s it take to raise $700M-plus for a biotech startup? Steve Harr has some thoughts on that

Last week

Two Bay Area upstarts out to deliver on cell therapy 2.0 join forces on a quest: pursuing a Holy Grail in oncology ...

2 weeks ago

The FDA backs off a hasty — and damaging — emergency OK for a potentially dangerous Covid-19 drug

3 weeks ago

Don't missSee all

Covid-19 roundup: Vaccines will need to beat placebo by 50% to qualify for FDA OK; UK trial drops Kaletra

Yesterday

Takeda maps out a discovery alliance aimed at breaking through the safety and efficacy boundaries that limit the ...

Yesterday

Seattle Genetics, Genmab turn on TV for a highlight reel in cervical cancer — but a rival biotech promises a better ...

2 days ago

UPDATED: Gilead opts for $3,120 US insurer price for Covid-19 drug remdesivir — but some say it should be free

3 days ago

Endpoints Standouts

The 20 under 40: Inside the next generation of biopharma leaders

2 months ago

Here are the 52 new drugs approved by the FDA in 2019. Who won? Who lost? And who just survived to 2020?

6 months ago

Special report: Twenty extraordinary women in biopharma R&D who worked their way to the top

7 months ago

[Video] Celebrating trial failures, changing the culture and allying with California dreamers: R&D chief Hal Barron ...

8 months ago

Peer review See all

Jun

26

Inovio adds two to the leadership team; Adrian Woolfson is out at Sangamo

Jun

19

Boehringer Ingelheim nabs new US president and CEO; AstraZeneca vet hops aboard Novavax as CMO

Jun

12

'Rising star' CEO recounts path from pre-med to breakthrough meds; Dendreon taps Big Pharma vet Jason O'Neill as CEO

Jun

5

David Chang steps up to CEO spot at WuXi's cell and gene therapy CDMO; David Meline is the new CFO at Moderna

May

29

Sierra Oncology brings on former Aimmune CEO to the helm; Flagship woos ex-Novartis exec Fabrice Chouraqui

R&D channel feed

3 days ago

Second death triggers hold on Astellas' $3B gene therapy biotech's lead program, raising fresh concerns about AAV

Seven months after Astellas shelled out $3 billion to acquire the gene therapy player Audentes, the biotech company’s lead program has been put on hold following the death of 2 ...

READ MORE

Positive Covid-19 vaccine data? New mouse study? OWS inclusion? Yep, but somehow, the usual tidbits from Inovio ...

Yesterday

Kiniksa preps BLA as Regeneron drug cruises to a PhIII win — shares soar

2 days ago

latest in R&D

Bolt Biotherapeutics nabs $93.5M to push Provenge inventor's new idea deeper in the clinic

22 hours ago

Days after Intercept rejection, Akero surges on ‘unprecedented‘ NASH data

Yesterday

Covid-19 has roiled clinical trial plans around the world, raising concerns over the industry’s future on new drug approvals

Yesterday

UPDATED: Zynerba flunks another major trial, all but ending Fragile X hopes

Yesterday

FDA rejects Intercept’s pitch for NASH as CEO fires back at the agency’s ‘evolving’ guidelines

2 days ago

see latest stories

Pharma channel feed

Yesterday

New standard of care? FDA hands Pfizer, Merck KGaA an OK for Bavencio in bladder cancer

The breakthrough therapy designation Pfizer and Merck KGaA notched for Bavencio in bladder cancer has quickly paved way for a full approval. The PD-L1 drug is now sanctioned as ...

READ MORE

On a roll, Merck blazes through a new segment of the biomarker trail

2 days ago

Takeda takes a $200M hit after Novartis is forced to yank its marketing application for Xiidra

2 days ago

latest in Pharma

DBV lays off employees, scales down programs after receiving no word from FDA

5 days ago

Sanofi preps another round of layoffs as new execs look to slim down the global pharma in an ongoing reorganization — report

6 days ago

After 2 delays, Zogenix nabs FDA approval for epilepsy drug, sets price at 3X its GW Pharma competitor

6 days ago

UK Supreme Court strikes down Regeneron patents, opening door for Kymab

Last week

What's the hard cost of a pivotal drug trial? A lot less than you might expect

Last week

see latest stories

Coronavirus channel feed

3 days ago

Covid-19 roundup: Temasek leads a $250M raise for BioNTech as first Covid-19 mRNA vaccine data looms; China's military OKs first use of coronavirus vaccine

Singapore’s giant fund run by Temasek is putting some financial muscle behind BioNTech $BNTX as the Pfizer partner prepares to post the first cut of its data on their mRNA vaccine to ...

READ MORE

WHO ACT-Accelerator prioritizes global vaccine approach

2 days ago

Covid-19 roundup: Moderna enlists Catalent as manufacturing partner, securing fill-finish capacity for the first 100M ...

6 days ago

latest in Coronavirus

Covid-19 roundup: Anthony Fauci, Stephen Hahn testify in Congress; China's Sinopharm speeds into PhIII vaccine trial

Last week

Hahn testifies on Covid-19 response, says FDA on target to hit user fee goals

Last week

Lawmakers ask FDA to outline Covid-19 vaccine approval process

Last week

Covid-19 roundup: $71M from DoD to Inovio; Pigs provide clues on Oxford vaccine; Google lends supercomputing to antiviral hunt

Last week

Covid-19 roundup: In fifth open letter, Daniel O’Day touts inhalant remdesivir, promises 2M doses by year's end; Merck’s antiviral moves into PhII

Last week

see latest stories